![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CHODL |
Gene summary for CHODL |
![]() |
Gene information | Species | Human | Gene symbol | CHODL | Gene ID | 140578 |
Gene name | chondrolectin | |
Gene Alias | C21orf68 | |
Cytomap | 21q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9H9P2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140578 | CHODL | P127T-E | Human | Esophagus | ESCC | 1.13e-04 | 7.79e-02 | 0.0826 |
140578 | CHODL | P128T-E | Human | Esophagus | ESCC | 5.35e-05 | 2.49e-01 | 0.1241 |
140578 | CHODL | P130T-E | Human | Esophagus | ESCC | 1.68e-24 | 5.51e-01 | 0.1676 |
140578 | CHODL | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.48e-03 | 4.21e-01 | 0.343 |
140578 | CHODL | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.70e-10 | 7.07e-01 | 0.1829 |
140578 | CHODL | RNA-P3T-P3T-2 | Human | Lung | IAC | 4.78e-13 | 8.26e-01 | 0.1835 |
140578 | CHODL | RNA-P3T-P3T-4 | Human | Lung | IAC | 6.77e-09 | 5.90e-01 | 0.1859 |
140578 | CHODL | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.51e-02 | 1.77e-01 | -0.0166 |
140578 | CHODL | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.06e-02 | 1.88e-01 | -0.0132 |
140578 | CHODL | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 8.99e-07 | 2.80e-01 | -0.013 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
GO:00507705 | Cervix | CC | regulation of axonogenesis | 34/2311 | 154/18723 | 4.87e-04 | 4.76e-03 | 34 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00507724 | Cervix | CC | positive regulation of axonogenesis | 20/2311 | 79/18723 | 1.19e-03 | 9.57e-03 | 20 |
GO:00507676 | Cervix | CC | regulation of neurogenesis | 65/2311 | 364/18723 | 1.33e-03 | 1.05e-02 | 65 |
GO:00507694 | Cervix | CC | positive regulation of neurogenesis | 43/2311 | 225/18723 | 2.25e-03 | 1.61e-02 | 43 |
GO:00075173 | Cervix | CC | muscle organ development | 58/2311 | 327/18723 | 2.73e-03 | 1.85e-02 | 58 |
GO:00519622 | Cervix | CC | positive regulation of nervous system development | 48/2311 | 272/18723 | 6.60e-03 | 3.65e-02 | 48 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHODL | SNV | Missense_Mutation | rs780658002 | c.89N>G | p.Val30Gly | p.V30G | Q9H9P2 | protein_coding | deleterious(0) | benign(0.274) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CHODL | SNV | Missense_Mutation | c.611A>C | p.Gln204Pro | p.Q204P | Q9H9P2 | protein_coding | tolerated(0.27) | benign(0.036) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CHODL | SNV | Missense_Mutation | c.202N>A | p.Leu68Ile | p.L68I | Q9H9P2 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CHODL | SNV | Missense_Mutation | c.685N>G | p.Leu229Val | p.L229V | Q9H9P2 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
CHODL | SNV | Missense_Mutation | novel | c.322N>T | p.Asp108Tyr | p.D108Y | Q9H9P2 | protein_coding | deleterious(0) | possibly_damaging(0.489) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CHODL | SNV | Missense_Mutation | c.146N>A | p.Ser49Tyr | p.S49Y | Q9H9P2 | protein_coding | deleterious(0.01) | possibly_damaging(0.486) | TCGA-CM-6167-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CHODL | SNV | Missense_Mutation | novel | c.457N>T | p.Ala153Ser | p.A153S | Q9H9P2 | protein_coding | tolerated(0.06) | possibly_damaging(0.568) | TCGA-G4-6295-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHODL | SNV | Missense_Mutation | c.289G>T | p.Gly97Cys | p.G97C | Q9H9P2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A00C-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
CHODL | SNV | Missense_Mutation | novel | c.475N>T | p.Gly159Cys | p.G159C | Q9H9P2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHODL | SNV | Missense_Mutation | novel | c.263C>T | p.Thr88Ile | p.T88I | Q9H9P2 | protein_coding | tolerated(0.16) | possibly_damaging(0.882) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |